Hormonal
Tirzepatide, a dual GLP-1 and GIP receptor agonist, produces superior weight loss (up to 20.9%) and visceral fat reduction compared to other anti-obesity medications.
Tirzepatide is currently the most effective pharmacological tool for significant weight loss, capable of reducing body weight by over 20% in clinical trials. It works by mimicking two gut hormones (GLP-1 and GIP) to reduce appetite and fat storage. While highly effective, it requires weekly injections and careful monitoring for gastrointestinal side effects like nausea.
In the SURMOUNT-1 trial, participants without diabetes experienced a mean weight loss of up to 20.9% after 72 weeks of treatment with the highest dose of tirzepatide, compared to a mere 3.1% in the placebo group.
Why this rating
Based on a Phase 3 randomized clinical trial (SURMOUNT-1) cited in the text.
Source
The Growing Obesity Epidemic: Integrating Lifestyle, Pharmacological, and Surgical Interventions for Effective Management
Jan Siwiec et al. · Journal of Education Health and Sport · 2025
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →